Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | P-BCMA-ALLO1 + Rimiducid |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
P-BCMA-ALLO1 | P-BCMA-ALLO 1|P-BCMA-ALLO-1 | P-BCMA-ALLO1 are allogeneic T lymphocytes engineered to express a single-domain variable heavy chain chimeric antigen receptor (VCAR) targeted against B-cell maturation antigen (BCMA), an undisclosed drug selection gene, and a caspase-based safety switch gene, which potentially inhibit tumor growth (Blood (2019) 134 (Supplement_1): 4445). | ||
Rimiducid | AP1903|AP-1903|AP 1903 | Rimiducid (AP1903) is a small molecule that selectively binds to mutant FKBP12 and induces dimerization and downstream signaling, which can be used to activate a safety switch in transplanted cells to potentially induce apoptosis and prevent graft-versus-host disease (PMID: 9724721, PMID: 22047558, PMID: 28697888). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04960579 | Phase I | P-BCMA-ALLO1 + Rimiducid | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) | Recruiting | USA | 0 |